Osteoarthritis pain in dogs: does tramadol vs placebo reduce pain scores and improve mobility? — POSSIBLE (the treatment made no difference)

In dogs with osteoarthritis, does tramadol vs placebo reduce pain scores and improve mobility?

Shelf #510 · gate-verified and displayed under the developer's blinded-trial rule

POSSIBLE (the treatment made no difference): In the decisive trial (Budsberg 2018), a randomised, blinded, placebo-controlled crossover study in 40 dogs with elbow or stifle osteoarthritis (35 completed), 10 days of tramadol 5 mg/kg orally every 8 hours produced no significant change from baseline in vertical impulse or peak vertical force and no significant improvement in Canine Brief Pain Inventory scores — the same null as placebo — while the carprofen positive-control arm improved significantly on all of these, showing the trial could detect a real effect. The second trial (Malek 2012), a randomized, double-blinded placebo-controlled trial in 49 client-owned dogs with hip osteoarthritis, agrees on the objective measure: kinetic gait analysis revealed no significant treatment effects for any group. Its one discordant signal is subjective — owner-questionnaire mobility improved in the tramadol group (P ≤ 0.001) — in a trial whose authors found placebo treatment effects evident with all variables studied, and whose abstract does not state that the questionnaire result separated tramadol from placebo. Design class (a): randomisation and blinding are both established by carded records (Budsberg 2018, 'Randomized, blinded, placebo-controlled crossover study'; Malek 2012, 'randomized, double-blinded placebo-controlled'). The honest limits: tramadol was tested at one dose regimen for 10–14 days, in elbow/stifle (Budsberg) and hip (Malek) osteoarthritis only, and the stamp is POSSIBLE rather than LIKELY because of the single discordant subjective signal in Malek. Drafted Nov 10, 2026 (VetMed build, topic #510); all figures from abstracts fetched and verified at drafting.

Budsberg 2018: 10 days of tramadol gave no benefit over placebo on ground reaction forces or pain inventory scores in dogs with elbow or stifle osteoarthritis (the treatment made no difference), while carprofen improved significantly

Randomized, blinded, placebo-controlled crossover study (record's own wording: 'Randomized, blinded, placebo-controlled crossover study'; publication type: Clinical Trial, Veterinary)

Who: Dogs: 40 dogs with clinical osteoarthritis of the elbow or stifle joint (35 completed the study). Each dog orally received, in random order for 10 days each, separated by a minimum 7-day washout: placebo three times daily; carprofen 2.2 mg/kg every 12 hours (morning and night) with placebo at midday; or tramadol hydrochloride 5 mg/kg every 8 hours — all treatments identically appearing. Vertical ground reaction forces (vertical impulse and peak vertical force) and Canine Brief Pain Inventory (CBPI) scores were measured at baseline and at the end of each treatment period.

Result: No significant changes from baseline in vertical impulse and peak vertical force were identified for placebo and tramadol treatments; these values increased significantly with carprofen treatment, and changes from baseline were significantly greater with carprofen versus placebo or tramadol. A significant improvement from baseline in CBPI scores was identified with carprofen treatment but not placebo or tramadol treatment. The authors conclude that 10 days of tramadol as administered (5 mg/kg, PO, q 8 h) provided no clinical benefit for dogs with osteoarthritis of the elbow or stifle joint.

Watch out: A single dose regimen tested for 10 days in two joints only — the card does not exclude an effect at other doses or over longer treatment, and it says nothing about tramadol for acute or post-operative pain, a different question. The carprofen arm matters: because a known effective drug separated clearly in the same dogs, the tramadol null cannot be dismissed as an insensitive trial.

Budsberg SC, Torres BT, Kleine SA, Sandberg GS, Berjeski AK. Lack of effectiveness of tramadol hydrochloride for the treatment of pain and joint dysfunction in dogs with chronic osteoarthritis. J Am Vet Med Assoc. 2018;252(4):427-432. PMID: 29393744. Registry ID: none in the record. MeSH: Analgesics, Opioid/administration & dosage, therapeutic use* · Animals · Cross-Over Studies · Dog Diseases/drug therapy* · Dogs · Elbow Joint* · Female · Male · Osteoarthritis/complications, drug therapy, veterinary* · Pain/etiology, veterinary · Pain Measurement/veterinary · Random Allocation · Stifle* · Tramadol/administration & dosage, therapeutic use* · Treatment Outcome

Malek 2012: kinetic gait analysis showed no significant treatment effects in hip osteoarthritis, although owner-questionnaire mobility improved in the tramadol group and placebo effects were evident on all variables

Randomized, double-blinded placebo-controlled prospective trial (record's own wording: 'randomized, double-blinded placebo-controlled prospective trial'; publication type: Randomized Controlled Trial)

Who: Dogs: 49 client-owned dogs with hip osteoarthritis enrolled after a 1-week baseline period and randomly assigned for 2 weeks to ABT-116 (a transient receptor potential vanilloid 1 antagonist), carprofen, tramadol, or placebo. Outcome measures were physical examination parameters, owner questionnaire, activity monitoring, gait analysis, and use of rescue medication. The record's abstract does not state the tramadol dose or the number of dogs per group.

Result: Treatment with carprofen (P ≤ 0.01) and tramadol (P ≤ 0.001) led to improved mobility assessed by owner questionnaire. Kinetic gait analysis did not reveal significant treatment effects. Nighttime activity was increased after ABT-116 treatment (P = 0.01), and acute hyperthermia developed after ABT-116 (P < 0.001). Use of rescue treatment decreased in the ABT-116 and carprofen groups (P < 0.001). Placebo treatment effects were evident with all variables studied. The authors suggest the results reflect caregiver bias or regression to the mean, and conclude ABT-116 is not as effective as carprofen or tramadol for hip arthritis pain in client-owned dogs.

Watch out: The tramadol signal in this trial is subjective (owner questionnaire) in a study that itself documented placebo effects on every variable, and the abstract does not state that the questionnaire improvement separated tramadol from placebo — so it is not carded here as a tramadol-versus-placebo difference. On the objective measure (kinetic gait analysis) this trial agrees with Budsberg 2018: no significant treatment effect.

Malek S, Sample SJ, Schwartz Z, Nemke B, Jacobson PB, Cozzi EM, Schaefer SL, Bleedorn JA, Holzman G, Muir P. Effect of analgesic therapy on clinical outcome measures in a randomized controlled trial using client-owned dogs with hip osteoarthritis. BMC Vet Res. 2012;8:185. PMID: 23035739. Registry ID: none in the record. MeSH: Analgesics, Opioid/adverse effects, therapeutic use · Animals · Anti-Inflammatory Agents, Non-Steroidal/adverse effects, therapeutic use · Body Temperature/drug effects · Carbazoles/adverse effects, therapeutic use* · Dog Diseases/drug therapy* · Dogs · Double-Blind Method · Female · Heart Rate/drug effects · Indazoles/adverse effects, therapeutic use* · Lameness, Animal/drug therapy · Male · Osteoarthritis, Hip/drug therapy, veterinary* · Pain/drug therapy, veterinary · Phenylurea Compounds/adverse effects, therapeutic use* · Placebo Effect · Respiration/drug effects · Tramadol/adverse effects, therapeutic use* · Treatment Outcome

Synthesis: tramadol showed no objective or pain-inventory benefit over placebo in the blinded crossover trial whose positive control worked, and no gait effect in the second blinded trial; the only positive signal is a subjective owner-questionnaire result in a trial with documented placebo effects on all measures

Synthesis

Who: Synthesis of the cards above: Budsberg 2018 (40 dogs with elbow or stifle osteoarthritis, randomised blinded placebo-controlled crossover, tramadol 5 mg/kg q 8 h for 10 days, carprofen positive control) and Malek 2012 (49 client-owned dogs with hip osteoarthritis, randomized double-blinded placebo-controlled, 2 weeks).

Result: (1) Objective gait: no significant change from baseline in vertical impulse or peak vertical force with tramadol in Budsberg, and no significant treatment effects on kinetic gait analysis in Malek. (2) Pain scores: CBPI improved significantly with carprofen but not with tramadol or placebo in Budsberg. (3) Subjective mobility: owner-questionnaire mobility improved in the tramadol group in Malek (P ≤ 0.001), in the presence of placebo effects on all variables and with no statement in the record that this separated tramadol from placebo.

Watch out: Both trials are short (10–14 days) and test tramadol essentially at one regimen for chronic osteoarthritis pain; neither addresses acute pain, other joints beyond hip/elbow/stifle, or tramadol combined with an NSAID. The shelf answer is about tramadol alone versus placebo for osteoarthritis, not about whether an individual dog might appear to respond — caregiver placebo effects are documented in exactly this setting.

Synthesis of Budsberg SC et al. PMID: 29393744; Malek S et al. PMID: 23035739. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.